Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
Jan‐Niklas Eckardt(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Jan Moritz Middeke(Fresenius (Germany)), Michael Krämer(University Hospital Carl Gustav Carus), Karsten Spiekermann(German Cancer Research Center), Sebastian Stasik, Utz Krug(Klinikum Leverkusen), Wolfgang E. Berdel(University Hospital Münster), Karsten Wendt, Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Klaus H. Metzeler(University Hospital Leipzig), Carsten Müller‐Tidow(Heidelberg University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Dennis Görlich(University of Münster), Julia-Annabell Georgi(University Hospital Carl Gustav Carus), Peter Heisig(Institute of Software), Mathias Hänel(Klinikum Chemnitz), Christoph Schliemann(University Hospital Münster), Jan Braess, Frank Kroschinsky(University Hospital Carl Gustav Carus), Maher Hanoun(Essen University Hospital), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Tobias Herold(German Cancer Research Center), Hubert Serve(Goethe University Frankfurt), Tim Sauer(Heidelberg University), Martin Kaufmann(Robert Bosch Hospital), Cristina M. Sauerland, Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Kerstin Schäfer‐Eckart(Nuremberg Hospital), Johannes Schetelig(University Hospital Carl Gustav Carus), Bernhard J. Woermann(Charité - Universitätsmedizin Berlin), Christian Thiede(University Hospital Carl Gustav Carus)
Cited by 47
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k